Some studies have indicated that ER-β is a biomarker linked to more aggressive breast cancer [65], and our data may suggest that ER-β may be biomarker of response to anti-IGF-IR therapy or that targeting ER-β in TNBC could be a different approach for downregulating IGF signalling. This evidence concerns the gene IGF1 and breast carcinoma.